Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab for Brain Radionecrosis (BRADI)
NCT06471465Phase 3Recruiting
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Apr 2025
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in brain radionecrosis comparing Bevacizumab + Prednisolone with Placebo + Prednisolone (2 arms). Primary endpoint: Efficacy at 90 days on decrease in corticosteroids and neurological symptoms. Started Apr 2025; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
brain radionecrosis
Beyond the preview
Go deeper on NCT06471465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06471465.